MISSISSAUGA, Ontario–(BUSINESS WIRE)–MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that, further to its Press Release dated April 7, 2025, when it announced the Initial Closing of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated February 25, 2025, it has made application to the TSX Venture Exchange for an extension of 30 days to June 6, 2025, within which to effect further closings on this Private Placement. The Initial Closing, effective April 3, 2025, comprised the issuance of 13,500,000 Units (as described in detail in the Company’s Press Release dated April 7, 2025) and raised cash proceeds of $945,000. With the extension of the final date for this Placement, it is anticipated that further Closings will take place, for up to a maximum of a further 22,214,285 Units at $0.07 per Unit, to raise up to a further $1,555,000. As previously announced, it is anticipated that, subject to compliance with relevant regulatory provisions, certain Insiders may participate in this Placement at a subsequent Closing, though to not more than 25% of the total funds raised. Funds raised in this Placement will be directed towards continuing development of the Company’s leading edge SIAscopy® on DermSecure® telemedicine platform, building out the launch of its technology into the occupational health marketplace, and general corporate purposes.
About MedX Health Corp.:
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the U.S., Australia, New Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Contacts
Bill Mitoulas, Investor Relations
MedX Health Corp.
bill@medxhealth.com
+1-416-479-9547
or
Stephen Lockyer, President
+1-905-670-4428
